- $521.22m
- $286.53m
- $83.33m
- 52
- 16
- 63
- 39
Annual cashflow statement for Regenxbio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -111 | 128 | -280 | -263 | -227 |
| Depreciation | |||||
| Non-Cash Items | 34.6 | 41.3 | 45.9 | 38.7 | 32.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 14.2 | 40.2 | 14 | -10.9 | 5.53 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -54.1 | 219 | -207 | -218 | -173 |
| Capital Expenditures | -26.9 | -84.2 | -30.7 | -9.96 | -2.44 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 150 | -322 | 18.8 | 201 | 106 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 123 | -407 | -11.9 | 191 | 103 |
| Financing Cash Flow Items | 193 | -27.2 | -33.1 | -42.8 | -40.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 200 | 195 | -28.8 | -35 | 92.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 269 | 7.48 | -248 | -62.4 | 23 |